

WHAT IS CLAIMED IS:

1. A method for screening pharmaceuticals comprising detecting cross talk between intracellular signal from TGF- $\beta$  family receptor and an intranuclear receptor.

2. A method for screening pharmaceuticals which induce cross talk between intracellular signal from TGF- $\beta$  family receptor and an intranuclear receptor.

3. A method for screening pharmaceuticals which inhibit cross talk between intracellular signal from TGF- $\beta$  family receptor and an intranuclear receptor.

4. A method for screening pharmaceuticals comprising detecting interaction between an intranuclear receptor and Smad molecule.

5. The method for screening pharmaceuticals as claimed in Claim 4, characterized in that said interaction with said Smad molecule is detected by using the Two-Hybrid System.

6. The method for screening pharmaceuticals as claimed in Claim 4, characterized in that said interaction with said Smad molecule is detected by using antigen-antibody reaction.

7. A method for screening of pharmaceuticals comprising detecting interaction between a transcription coupling factor and Smad molecule.

8. The method for screening pharmaceuticals as

FOI b6 b7C

Sub A3  
25 limit

Sub A3  
canceled

claimed in Claim 7, characterized in that said  
transcription coupling factor is CBP and/or p300.

5 9. A method for screening of pharmaceuticals  
comprising detecting interaction among an intranuclear  
receptor, Smad molecule and an transcription coupling  
factor.

10 10. The method for screening pharmaceuticals as  
described in Claim 9, characterized in that said  
transcription coupling factor is CBP and/or p300.

11. The method for screening pharmaceuticals as  
described in Claim 1, characterized in that said  
intranuclear receptor is vitamin D receptor.

15 12. The method for screening of pharmaceuticals as  
described in Claim 1, characterized in that said Smad  
molecule is Smad3.

20 13. A method for molecular design for  
pharmaceuticals characterized by using steric structural  
data of the binding site of Smad molecule with an  
intranuclear receptor and CPB and/or p300 as a  
transcription coupling factor.

add A4